Starting Dose for NAD+ Infusions in a Wellness IV Center
The recommended starting dose for Nicotinamide adenine dinucleotide (NAD+) infusions in a wellness IV center is 250 mg per day, as this dose has been shown to be safe and effective in increasing blood NAD+ levels in healthy subjects. 1
Dosing Considerations
- NAD+ is an abundant molecule vital to all living cells, with levels that decline with age, correlating with age-related diseases 2
- Initial dosing of 250 mg/day has been demonstrated to be safe in clinical trials with no observed adverse effects 1
- This starting dose significantly increases blood NAD+ levels (by approximately 100%) without causing adverse effects 3
- Higher doses can be considered after evaluating patient tolerance to the initial dose, with studies examining doses up to 1000 mg twice daily 3
Administration Protocol
- NAD+ should be administered via slow IV infusion to minimize potential side effects 4
- For IV administration, electronic infusion pumps are preferred over gravity drip methods for precise dosing 4
- The infusion rate should be carefully controlled, as with other IV medications, to prevent adverse reactions 5
- Total infusion time should typically be between 10-60 minutes, similar to other IV infusions, to reduce risk of side effects 5
Safety Profile
- NAD+ precursors have been shown to be well-tolerated in healthy middle-aged and older adults 6
- No significant abnormalities in physiological or laboratory tests have been observed with proper dosing 1
- The No-Observed-Adverse-Effect-Level (NOAEL) in animal studies is 1,000 mg/kg/day in females and 500 mg/kg/day in males 2
- Monitoring vital signs during infusion is recommended, similar to protocols for other IV medications 5
Dose Titration
- After establishing tolerance at 250 mg, doses may be gradually increased if needed 3
- Studies have safely titrated doses up to 1000 mg twice daily over a period of 7-8 days 3
- Dose increases should be gradual with careful monitoring for adverse effects 7
- The correlation between NAD+ levels and pulse rate should be considered when adjusting doses 1
Monitoring Recommendations
- Patients should be kept under regular observation during and shortly after infusion (monitoring symptoms, heart rate/rhythm, oxygen saturation, blood pressure, etc.) 5
- Continuous monitoring of vital signs during administration is recommended, especially when using higher doses 5
- Be prepared to adjust infusion rates if adverse effects occur 5
- Follow-up assessment after therapy is recommended to evaluate clinical response 8
Potential Contraindications and Cautions
- As with any IV therapy, proper patient screening should be conducted prior to administration 5
- Consultation with a clinical pharmacist may be advisable when initiating NAD+ IV therapy programs 9
- Patients with cardiac conditions may require additional monitoring due to potential effects on heart rate 1
- For patients with renal impairment, dose adjustments may be necessary as with other IV medications 5